STING1 and neoplasm: STING targets Hexokinase II (HK2) to inhibit its hexokinase activity, thereby suppressing aerobic glycolysis, reducing lactate production, and inhibiting tumor growth.217 STING agonists have also been found to sensitize tumors to immune checkpoint inhibitors.218 This discovery suggests a synergistic potential where activating the STING pathway can enhance the effectiveness of treatments that target immune checkpoints.